Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Celsion Corp (CLSN)

Celsion Corp (CLSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price...

CLSN : 1.0600 (-10.92%)
Poster on Celsion Corporation's Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer

Company reports further strengthening of R0 resection results in patients treated with GEN-1

CLSN : 1.0600 (-10.92%)
CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING

Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of...

CLSN : 1.0600 (-10.92%)
Celsion Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 19, 2021 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 19, 2021 at 11:00 AM Eastern...

CLSN : 1.0600 (-10.92%)
Celsion Corporation Reports 2020 Financial Results and Provides Business Update

Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet

CLSN : 1.0600 (-10.92%)
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at...

CLSN : 1.0600 (-10.92%)
Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

CLSN : 1.0600 (-10.92%)
Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Company's Phase I/II OVATION...

CLSN : 1.0600 (-10.92%)
Celsion Corporation to Participate in the Virtual 33ʳ�? Annual Roth Conference

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings...

CLSN : 1.0600 (-10.92%)
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement

CLSN : 1.0600 (-10.92%)
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years

CLSN : 1.0600 (-10.92%)
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases

CLSN : 1.0600 (-10.92%)
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI.

CANF : 2.09 (-4.13%)
CFMS : 0.8469 (+2.16%)
CLSN : 1.0600 (-10.92%)
CTXR : 1.7300 (+1.17%)
VUZI : 22.93 (-0.99%)
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, CLSN, MARK, PSTV, and SNES.

CANF : 2.09 (-4.13%)
PSTV : 2.08 (+0.97%)
CLSN : 1.0600 (-10.92%)
MARK : 1.8300 (-3.68%)
SNES : 1.4700 (-2.00%)
Celsion Corporation Announces Formation of Vaccine Advisory Board

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2

CLSN : 1.0600 (-10.92%)
Thinking about buying stock in Seelos Therapeutics, Celsion Corp, Zosano Pharma, Outlook Therapeutics, or Infinity Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEEL, CLSN, ZSAN, OTLK, and INFI.

INFI : 2.98 (-3.25%)
OTLK : 1.8200 (-4.21%)
SEEL : 5.26 (-0.38%)
CLSN : 1.0600 (-10.92%)
ZSAN : 1.0200 (unch)
Celsion Corporation Issues Letter to Stockholders

Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study,

CLSN : 1.0600 (-10.92%)
Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

CLSN : 1.0600 (-10.92%)
Celsion Corporation Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines

The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV)

CLSN : 1.0600 (-10.92%)
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase...

CLSN : 1.0600 (-10.92%)

Barchart Exclusives

The Wheat Bull Remains Intact At The Start Of The 2021 Crop Year
CBOT wheat futures are heading into the new crop year at the highest price in years. As the demand side of wheat’s fundamental equation is ever-increasing, consumers worldwide hope that 2021 is another year of bumper crops. Any supply issues could launch the wheat price even higher over the coming months. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar